In this interview, Michael Palese, MD, discusses subspecialization, its benefits for clinicians and patients, and what the future “office urologist” may look like.
Philip M. Hanno, MD, MPH
Switching a medication from prescription to over-the-counter status comes with challenges and risks, and is not always successful. In this interview, Roger Dmochowski, MD, discusses the pros and cons of OTC medications and explains the hurdles facing potential OTC products for urologic conditions.
In this interview, Sarah E. McAchran, MD, discusses the need for urology-gynecology collaboration, the background behind the ABMS recognizing the female pelvic medicine and reconstructive surgery subspecialty, and how barriers to full integration of providers treating pelvic floor disorders can be overcome.
In this interview, Karl-Erik Andersson, MD, PhD, discusses current treatments for common voiding dysfunctions and future directions, including central nervous system agents and combination therapies.
Articles in this issue of Urology Times highlight two of the more interesting abstracts on interstitial cystitis/bladder pain syndrome (IC/BPS) presented at the 2012 AUA annual meeting in Atlanta. They illustrate the relentless progress being made in the efforts to improve the lives of patients with this difficult-to-treat syndrome.
In this podcast, Dr. Phil Hanno interviews Dr. Michael Chancellor on the potential role of botulinum toxin in urology.
Urology has always been a fascinating and somewhat hybrid specialty in
the field of medicine. First and foremost, it has been a surgical specialty,
requiring many years of intense surgical training to master. Many of us
have been drawn to urology because of the wide assortment of surgical procedures
and the ability to put to use the highest technological advancements in
the course of our work.